Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

NCT03311503 is registered in ClinicalTrials.gov with David Williams as lead sponsor.

NCT NCT03311503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03311503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Lead sponsor
David Williams
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 26, 2018
Completion date
January 1, 2028
Enrollment
12 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

gene therapy, severe combined immunodeficiency, x linked